Complement C3f serum levels may predict breast cancer risk in women with gross cystic disease of the breast

Aldo Profumo, Rosa Mangerini, Alessandra Rubagotti, Paolo Romano, Gianluca Damonte, Pamela Guglielmini, Angelo Facchiano, Fabio Ferri, Francesco Ricci, Mattia Rocco, Francesco Boccardo

Research output: Contribution to journalArticlepeer-review


Gross cystic disease (GCDB) is a breast benign condition predisposing to breast cancer. Cryopreserved sera from GCDB patients, some of whom later developed a cancer (cases), were studied to identify potential risk markers. A MALDI-TOF mass spectrometry analysis found several complement C3f fragments having a significant increased abundance in cases compared to controls. After multivariate analysis, the full-length form of C3f maintained a predictive value of breast cancer risk. Higher levels of C3f in the serum of women affected by a benign condition like GCDB thus appears to be correlated to the development of breast cancer even 20. years later. Biological significance: Increased complement system activation has been found in the sera of women affected by GCDB who developed a breast cancer, even twenty or more years later. C3f may predict an increased breast cancer risk in the healthy population and in women affected by predisposing conditions.

Original languageEnglish
Pages (from-to)44-52
Number of pages9
JournalJournal of Proteomics
Publication statusPublished - Jun 24 2013


  • Breast cancer risk
  • Complement C3f
  • Peptidome profile
  • Serum

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics


Dive into the research topics of 'Complement C3f serum levels may predict breast cancer risk in women with gross cystic disease of the breast'. Together they form a unique fingerprint.

Cite this